المؤلفون: Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies

المصدر: Endocrinology and Metabolism, Vol 34, Iss 3, Pp 247-262 (2019)

مصطلحات موضوعية: glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, diabetes mellitus, type 2, weight loss, body composition, lean body mass, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

الوصف: Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) are novel glucose-lowering therapies that have been shown to induce clinically significant reductions in body weight. However, this weight loss may not be attributed solely to fat mass (FM). Given the importance of skeletal muscle and lean body mass (LBM) on cardio-metabolic health and physical function, we reviewed the available literature reporting the effects of GLP-1RAs and SGLT2is on body composition. Results demonstrate that, in most circumstances, the weight loss associated with both therapies predominantly comprises a reduction in FM, although significant heterogeneity exists between studies. In over half of the studies identified, the proportion of LBM reduction ranged between 20% and 50% of total weight lost, which is consistent with diet-induced weight loss and bariatric surgery. No clear differences existed between GLP-1RAs and SGLT2is. Consequently, the loss of LBM and skeletal muscle associated with weight loss induced by GLP-1RAs and SGLT2is warrants attention. Strategies to preserve skeletal muscle and improve physical function, for example through structured exercise, are of great importance.

وصف الملف: electronic resource

العلاقة: https://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-34-247.pdfTest; https://doaj.org/toc/2093-596XTest; https://doaj.org/toc/2093-5978Test

الوصول الحر: https://doaj.org/article/1cf3b01d971c41eab6a25daf8739ec89Test

المساهمون: Jaewon Oh, Seung Hyun Lee, Chan Joo Lee, Seok Min Kang, Kang, Seok Min

مصطلحات موضوعية: Heart failure, Sodium-glucose cotransporter, Type 2 diabetes

الوصف: Results from cardiovascular outcome trials (CVOT) with 5 different sodium-glucose co-transporter 2 inhibitors (SGLT2i; empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, sotagliflozin), initially developed for their glucose-lowering effect by blocking tubular glucose reabsorption in kidney, have been shown to decrease the risk of heart failure hospitalization (HFH) across a range of patients with and without atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). Following these CVOT results, SGLT2i (dapagliflozin, empagliflozin, sotagliflozin) also were reported to reduce HFH and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of existence or absence of T2DM. Ongoing studies have been conducted to evaluate the clinical benefit of SGLT2i (empagliflozin, dapagliflozin) in patients with heart failure with preserved ejection fraction (HFpEF). Although SGLT2i brought us to the entrance of a new era for prevention of HF incidence and worsening of HF, the search for pivotal mechanism of SGLT2i to improve our pharmacological armamentarium should continue in order to protect every HF patient from fatal progression of HF disease. In this review, we summarized the updated clinical evidences on SGLT2i (rather than basic and translational evidence) for reduction of HF risk in T2DM patients and favorable clinical outcomes in both HFrEF and HFpEF patients. ; open

العلاقة: KOREAN CIRCULATION JOURNAL; J01952; OAK-2021-09301; https://ir.ymlib.yonsei.ac.kr/handle/22282913/187421Test; T202125075; KOREAN CIRCULATION JOURNAL, Vol.51(5) : 399-408, 2021-05

الإتاحة: https://doi.org/10.4070/kcj.2021.0070Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/187421Test

المؤلفون: Kim, HJ

المساهمون: 105743, 김, 혜진

مصطلحات موضوعية: Hypoglycemic agents, Sodium glucose cotransporter 2, Type 2 diabetes mellitus

الوصف: There are numerous glucose lowering agents in clinical use for type 2 diabetic patients, yet most do not achieve glycemic targets. Recently, inhibitors of the sodium glucose cotransporter 2 (SGLT2) have been developed, which show great potential of being a novel therapeutic option to treat type 2 diabetes. Many researches have turned their attention to the kidney as a target because renal glucose reabsorption is increased in type 2 DM. SGLT2 is a protein transporter that mediates glucose reabsorption from glomerular filtrates. In an insulinindependent manner, inhibition of SGLT2 increases urinary glucose excretion and decreases plasma glucose levels. To date, there are a few SGLT2 inhibiting agents being clinically studied both as a monotherapy and in combination with other antidiabetic agents. This review will focus on the efficacy of SGLT2 inhibitors based on clinical studies.

العلاقة: J022337431; http://repository.ajou.ac.kr/handle/201003/11482Test; https://synapse.koreamed.org/DOIx.php?id=10.4093/jkd.2014.15.3.146Test; The Journal of Korean Diabetes, 15(3). : 146-150, 2014

الإتاحة: https://doi.org/10.4093/jkd.2014.15.3.146Test
http://repository.ajou.ac.kr/handle/201003/11482Test